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MicroRNAs have emerged as important regulators of carcinogenesis. In the current study, we
observed that microRNA-202 (miR-202) is downregulated in hepatocellular carcinoma (HCC) cells
and tissues, indicating a signiﬁcant correlation between miR-202 expression and HCC progression.
Overexpression of miR-202 in HCC cells suppressed cell proliferation and tumorigenicity, while
downregulation of miR-202 enhanced the cells’ proliferative capacity. Furthermore, we identiﬁed
low-density lipoprotein receptor-related protein 6 (LRP6) as a direct target of miR-202. miR-202
suppresses the expression of LRP6 by binding to the 30-untranslated region (UTR) of its mRNA.
Finally, we found that silencing the expression of LRP6 is the essential biological function of miR-
202 during HCC cell proliferation. Collectively, our ﬁndings reveal that miR-202 is a potential tumor
suppressive miRNA that participates in carcinogenesis of human HCC by suppressing LRP6
expression.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers and is the third most common cause of cancer deaths in
the world. HCC is one of the most common types of cancer in Asian
countries, where chronic hepatitis or liver diseases are prevalent
[1]. Most patients with HCC are asymptomatic until the later stages
and their prognosis is generally very poor, with a survival rates 20–
65% for 1 year, 10–30% for 3 years and 10–20% for 5 years [2]. At
present, surgical resection is the best curative treatment for HCC.
Identiﬁcation of early stage HCC, which potentially meets the crite-
ria for resection, would improve the survival rate [3]. The prognosis
of HCC has not been improved despite signiﬁcant progress in the
diagnostic and therapy of HCC. Many studies have identiﬁed fac-tors associated with HCC survival, but the results are inconsistent
[2]. Speciﬁc and effective diagnostic biomarkers for early stage
HCC are needed urgently.
MicroRNAs (miRNAs), a class of endogenous non-coding small
RNAs of 20–22 nucleotides, have been found to negatively regulate
genes expression by targeting the 30 untranslated region (UTR) of
target mRNAs in a sequence-speciﬁc manner and are involved in
multiple biological processes [4,5]. Increasing numbers of reports
have shown that miRNAs have key roles in the progression of
various human cancers, where some miRNAs are identiﬁed as
onco-miRs and some as tumor suppressors [6–8]. Considering the
modulation of miRNAs during tumorigenesis, miRNAs are
currently considered as substantial novel biomarkers for tumor
diagnosis and therapy. miR-202 is located within a chromosomal
fragile site in 10q26, deletion of which is associated with endome-
trial and brain tumors [9–11]. Although miR-202 was observed to
be deregulated in gastric cancer, breast cancer, cervical squamous
cell carcinoma, colorectal cancer, follicular lymphoma and leuke-
mia [12–16], the effects of miR-202 on HCC have not been
documented.
The low-density lipoprotein receptor-related protein 6 (LRP6), a
member of the expanding low-density lipoprotein (LDL) receptor
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placenta, lung, kidney, pancreas, spleen, testis, ovary, liver, skeletal
muscle, prostate and the mucosal lining of the colon [17]. Li et al.
found that LRP6 is signiﬁcantly expressed in human colon cancer,
breast cancer, lung cancer, ﬁbrosarcoma, and kidney tumors. Over-
expression of LRP6 promotes cell proliferation and tumorigenesis
[18]. Liu et al. found that LRP6 expression is frequently upregulated
in breast cancer, and might deﬁne a class of breast cancer subtype
and may be considered as a putative target for therapy [19]. In
HCC, the transcripts and protein levels of LRP6 are upregulated in
cells and tissues, and overexpression of LRP6 enhanced HCC cells
proliferation, migration and invasion [20]. However, modulation
of LRP6 by miRNAs in HCC has not been reported.
In this study, we identiﬁed that microRNA-202 (miR-202) is
downregulated in HCC and that ectopic expression of miR-202 in
HCC cells leads to suppression of cell proliferation, tumorigenicity
and cell cycle progression. By contrast, inhibition of miR-202
enhances cell proliferation. Furthermore, miR-202 targets LRP6
directly by post-transcriptional downregulation. LRP6 plays essen-
tial role in miR-202-mediated proliferation of HCC cells. Collec-
tively, our present study demonstrated, for the ﬁrst time, that
miR-202 suppresses cell proliferation, tumorigenicity and cell cycle
progression in HCC cells by suppressing the expression of the LRP6
oncogene. Thus, miR-202 might be considered a potential tumor
suppressor in HCC.
2. Material and methods
2.1. Cell culture
Normal liver epithelial cells, THLE3, were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and
cultured according to the manufacturer’s instruction. The HCC cell
lines (BEL-7402, MHCC97L, MHCC97H, QGY-7703, HCCC-9810,
Hep3B, HepG2, and Huh7) were maintained in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (Invitrogen), 100 U/ml penicillin and
100 lg/ml streptomycin (Invitrogen), within a humidiﬁed atmo-
sphere containing 5% CO2 at 37 C.
2.2. Tissue specimens
Eight pairs of snap-frozen HCC tumor (Presented as T1–T8 in
Figs. 1 and 4) and matched normal tissues from adjacent regions,
which were diagnosed histopathologically at the Zhongnan Hospi-
tal of Wuhan University from 2011 to 2012, were immediately
stored in liquid nitrogen after surgery until further use. For theFig. 1. Expression of miR-202 is downregulated in HCC. (A) Real-time PCR analysis o
carcinoma cell lines. (B) Comparison of miR-202 levels in HCC tissues and normal cont
hepatic tissues (ANT). The average miR-202 expression was normalized using U6 expres
non-cancerous hepatic tissues, as measured using a published micro-array-based high-th
the mean ± S.D. of three independent experiments. ⁄P < 0.05.use of the clinical materials for research purposes, the Institutional
Research Ethics Committee approved the study, and prior patient
consent was obtained.
Analysis of miR-202 expression in HCC tissues compared with
that in matched non-cancerous hepatic tissues was using a pub-
lished microarray-based high-throughput assessment (n = 166,
P < 0.001; NCBI/GEO/GSE31384) [21]. The data were downloaded
from NCBI and analyzed using SPSS13.0 software.
2.3. Generation of stably engineered cell lines
The miR-202 expression plasmid, pMSCV-miR-202, was gener-
ated by cloning the genomic pre-miR-202 gene into plasmid
pMSCV-puro (Clontech Laboratories Inc., Mountain View, CA,
USA). pMSCV-puro-miR-202 was then cotransfected with plasmid
pIK into 293FT cells using the calcium phosphate transfection
method, as previously described [22]. Supernatants were collected
36 h after cotransfection and incubated with HCC cells to be in-
fected for 24 h. Puromycin (1.5 lg/ml, Sigma, Saint Louis, MO,
USA) was used to select stably transduced cells over 10 days.
2.4. RNA extraction and real-time quantitative PCR
Total cellular RNAwas extracted using the TRIzol solution (Invit-
rogen), according to themanufacturer’s protocol. Reverse transcrip-
tion and Real-time PCR were performed using RT Real-Time™ SYBR
Green (Bio-Rad Laboratories, Berkeley, CA, USA). The housekeeping
gene glyceraldehyde phosphate dehydrogenase (GAPDH) and the
small nuclear RNA U6 were used as internal controls for mRNAs
and microRNA, respectively. The primers used were as follows:
MYC forward: 50-TCAAGA GG CGAACACACAAC-30, MYC reverse: 50-
GGCCTTTTCATTGTTTTCCA-30; Cyclin D1 forward: 50-AACTACCTGG
ACCGCTTCCT-30, Cyclin D1 reverse: 50-CCACTTGAGC TT GTTCAC-
CA-30; LEF1 forward: 50-CACTGTAAGTGATGAGGGGG-30, LEF1
reverse: 50-TGGATCTC TTTCTCCACCCA-30; GAPDH forward: 50-GACT
CATGACCACAGTCCAT GC-30, GAPDH reverse: 30-AGAGGCAGGGATG
ATGTTCTG-50.
Expression levels of genes were calculated as
2½ðCt of p21; CyclinD1ÞðCt of GAPDHÞÞ (Ct represents the threshold cycle
for each transcript). The relative expression of the miRNA was cal-
culated as 2½ðCt of miR202ÞðCt of U6ÞÞ.
2.5. Western blotting
Cellular proteins were prepared in sample buffer [62.5 mM
Tris–HCl (pH 6.8), 10% glycerol, 2% SDS] and heated for 10 min at
100 C. Equal quantities of protein were electrophoresed throughf miR-202 expression in normal liver epithelial cells THLE3 and in hepatocellular
rol, including eight paired cancerous tissues (T) and their adjacent non-cancerous
sion. (C) The expression of miR-202 in HCC tissues compared with that in matched
roughput assessment (n = 166, P < 0.001; NCBI/GEO/GSE31384). Each bar represents
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ﬂuoride (PVDF) membrane (Millipore, Billerica, MA, USA). The
membranes were incubated with anti-LRP6, anti-c-Myc, anti-Cy-
clin D1, anti-b-catenin, anti-Rb, anti-phosphorylated Rb and anti-
a-Tubulin antibodies (1:1000; Cell Signaling Technology, Danvers,
MA, USA), respectively.
2.6. Oligonucleotides, siRNA and transfection
A miR-202 mimic, a miR-202 inhibitor and a negative control
(NC) were purchased from RiboBio (RiboBio Co. Ltd, Guangzhou,
Guangdong, China). For depletion of LRP6, an siRNA was synthe-
sized and puriﬁed by RiboBio (The LRP6 siRNA sequence was
CCGATGCAATGGAGATGCAAA). Transfection of oligonucleotides
and siRNAs were performed using Lipofectamine 2000 (Invitro-
gen), according to the manufacturer’s protocol.
2.7. Luciferase assay
A region of the human LRP6 30-UTR (500–1500 bp) containing
two miR-202 binding sites was ampliﬁed by PCR and cloned into
vector pGL3 (Promega, Madison, WI, USA). The primers used were
as follows: LRP6-30UTR-up: 50-GCCCCGCGGCTCTGGTAAGATGCCAT
GAAGCTGT-30; LRP6-30UTR-dn: 30-GCCCTGCAGTGTCGAAGTACCGT
AGAATGGTCTC-50. One hundred nanograms of pGL3-LRP6-30UTR-
luciferase plasmid was transfected into HCC cells using the
Lipofectamine 2000 (Invitrogen). Luciferase and control signals
were measured at 48 h after transfection using the Dual Luciferase
Reporter Assay Kit (Promega), according to manufacturer’s instruc-
tion. Three independent experiments were performed and the data
were presented as the mean ± standard deviation (S.D.).
2.8. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay
Cells were seeded in 96-well plates. 100 ll of sterile MTT dye
(0.5 mg/ml, Invitrogen) was added to the cells at the indicated time
points, and the plate was incubated for another 4 h at 37 C. 150 ll
of dimethyl sulfoxide (DMSO) (Sigma) was then added and the
absorbance was measured at 570 nm, with 655 nm as the reference
wavelength. Three independent experiments were performed and
the data were presented as the mean ± S.D.
2.9. Colony formation assay
Cells were seeded in a 6-well plate (1  103 cells per well) and
cultured for 10 days. The colonies were then ﬁxed with 10% form-
aldehyde for 15 min and stained with 1.0% crystal violet for 5 min.
Three independent experiments were performed and the data were
presented as the mean ± S.D.
2.10. Anchorage-independent growth ability assay
The bottom layer comprising 1% complete medium agar (Sigma)
mixture was poured into a well of the 6-well plate. After solidiﬁca-
tion, cells (1  103) were trypsinized and suspended in 2 ml culture
medium plus 0.3% agar, and then plated on top of the bottom layer.
After 10 days incubation, colony sizes were measured with an ocu-
lar micrometer, and colonies greater than 0.1 mm in diameter were
counted. The experiment was performed for indepedently three
times for each cell line.
2.11. Flow cytometry analysis
All cells in a culture dish were harvested by trypsinization,
washed in ice-cold PBS, and ﬁxed in 80% ice-cold ethanol. Beforestaining, the cells were pelleted in a cooled centrifuge (4 C,
1000 rpm, 5 min) and resuspended in the cold PBS. RNAase
(2 lg/ml, Sigma) was added, and the cells were incubated at
37 C for 30 min, followed by incubation in propidium iodide
(20 lg/ml, Sigma) for 20 min. 20000 cells were analyzed on a ﬂow
cytometer (FACSCalibur; BD Biosciences, Bedford, MA, USA).
2.12. Statistical analysis
All data were expressed as the mean ± S.D. Student’s t test was
used to evaluate the signiﬁcance of the differences between two
groups of data in all the pertinent experiments. The P value re-
ported was two-sided, and a value of P < 0.05 was considered sta-
tistically signiﬁcant.3. Results
3.1. miR-202 is downregulated in HCC
The basal expression of miR-202 in HCC cell lines was assessed
by the real-time PCR analysis. Compared with the normal liver
epithelial cells THLE3, all eight HCC cell lines used in our study
(BEL-7402, MHCC97L, MHCC97H, QGY-7703, HCCC-9810, Hep3B,
HepG2 and Huh7) expressed a low level of miR-202 (Fig. 1A). The
comparative analysis showed that miR-202 was markedly down-
regulated in eight pairs of cancerous tissues compared with the
adjacent non-cancerous hepatic tissues (Fig. 1B).Moreover, analysis
using a published microarray-based high-throughput assessment
showed that miR-202 expression is signiﬁcantly downregulated in
HCC tissues compared with that in matched non-cancerous hepatic
tissues (n = 166, P < 0.001; NCBI/GEO/GSE31384) (Fig. 1C). Collec-
tively, these results suggested that miR-202 was downregulated
in HCC.
3.2. Ectopic expression of miR-202 inhibits HCC cell proliferation
in vitro
To investigate the function of miR-202 in HCC progression, HCC
cell lines QGY-7703 and HepG2 stably expressing miR-202 were
established (Fig. 2A). The result of MTT assay showed that ectopic
expression of miR-202 signiﬁcantly inhibited the growth rate of
both HCC cell lines compared with control cells (Fig. 2B). A colony
formation assay further revealed that ectopic expression of miR-
202 resulted in decreased cell proliferation of HCC cells (Fig. 2C).
Additionally, an anchorage-independent growth assay showed a
consistent result: QGY-7703-miR-202 and HepG2-miR-202
showed fewer and smaller-sized colonies (Fig. 2D), indicating that
cells overexpressing miR-202 had a signiﬁcantly reduced ability to
form colonies in soft agarose compared with control cells. The
same experiments were performed in another two HCC cell lines,
BEL-7402 and MHCC97H, and the similar results were obtained
(Supplemental Fig. 1A–C). Furthermore, ﬂow cytometry was car-
ried out to identify the speciﬁc phases of the cell cycle. As shown
in Fig. 2E, the percentage of cells at G0/G1 phase in the miR-202
overexpressing group was signiﬁcantly higher, and the percentage
of cells at S phase was much lower, than that of the control group.
These results suggested that upregulation of miR-202 inhibited the
proliferative capacity and tumorigenicity of HCC cells in vitro.
3.3. Inhibition of miR-202 promotes proliferation of HCC cells
To further test whether inhibition of miR-202 results in promo-
tion of HCC cell proliferation, a miR-202 inhibitor (miR-202-in)
was used in a loss-of-function study (Fig. 3A). The results showed
that suppression of miR-202 signiﬁcantly enhanced the growth
Fig. 2. Ectopic expression of miR-202 inhibits HCC cell proliferation. (A) Real-time PCR analysis of miR-202 expression in QGY-7703 and HepG2 cells stably expressing miR-
202. (B) MTT-analysis of cell growth rates for different stable cell lines at indicated times after seeding. (C) Representative micrographs (left panel) and quantiﬁcation (right
panel) of cell colonies in the indicated HCC cell lines, as determined by a colony formation assay. (D) Representative micrographs (left panel) and quantiﬁcation (right panel)
of colony formation, as determined by anchorage-independent growth ability assay. Colonies larger than 0.1 mm were scored. (E) Flow cytometry analysis of indicated HCC
cells. Each bar represents the mean ± S.D. of three independent experiments. ⁄P < 0.05.
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202 inhibitor compared with that of NC transfected cells (Fig. 3B
and C). An anchorage-independent growth assay also revealed that
both cells transfected with miR-202 inhibitor produced more and
larger-colonies than the negative control (NC) cells (Fig. 3D). Inhib-
iton of miR-202 was also performed in another two HCC cell lines,
BEL-7402 and MHCC97H, and the similar results were obtained
(Supplemental Fig. 2A–C). In addition, ﬂow cytometry revealed a
dramatic decrease in the percentage of cells at G1/G0 phase andan increase in the percentage of cells at S phase in miR-202 inhib-
itor-transfected cells compared with NC transfected cells (Fig. 3E).
These results suggested that downregulation of miR-202 promoted
the proliferation and tumorigenicity of HCC cells.
3.4. LRP6 is a direct target of miR-202
To explore the mechanism underlying the growth inhibition by
miR-202 in HCC cells, we used publicly available algorithms
Fig. 3. Inhibition of miR-202 enhances HCC cell proliferation. (A) Real-time PCR analysis of miR-202 expression in QGY-7703 and HepG2 cells transfected with miR-202
inhibitor or NC. (B) MTT-analysis of the proliferation ability of HCC cells transfected with miR-202 inhibitor (miR-202-in) or NC analyzed. (C) Representative micrographs
(left) and quantiﬁcation (right) of cell colonies in indicated HCC cell lines, as determined by a colony formation assay. (D) The ability of tumorigenicity of HCC cells transfected
with miR-202 inhibitor or NC, as measured by an anchorage-independent growth ability assay. Colonies larger than 0.1 mm were scored. (E) Flow cytometry analysis of
indicated HCC cells transfected with miR-202 inhibitor or NC. Each bar represents the mean ± S.D. of three independent experiments. ⁄P < 0.05.
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miR-202 in humans. The results showed that there are two miR-
202 binding sites in LRP6mRNA 30UTR (Fig. 4A). As predicted, wes-
tern blotting showed that LRP6 expression was downregulated by
ectopic miR-202 and upregulated by miR-202 inhibitor in both
QGY-7703 and HepG2 cells (Fig. 4B). To further conﬁrm whether
LRP6 is a direct target of miR-202, the pGL3-LRP6-30-UTR-lucifer-
ase reporter was constructed, which contains two putative miR-
202 binding sites. The luciferase reporter assay showed that ecto-pic expression of miR-202 decreased the luciferase activity of the
pGL3-LRP6-30-UTR-luciferase reporter, and suppression of miR-
202 increased luciferase production. By contrast, a miR-202 mu-
tant containing three altered nucleotides in the seed sequence
failed to show an inhibitory effect on the luciferase activity
(Fig. 4C). It was reported previously that LRP6 is closely correlated
with Wnt/b-catenin signaling activity; therefore, we examined the
mRNA expression levels of downstream genes in the Wnt/b-cate-
nin signaling pathway. The downstream genes regulated by Wnt/
Fig. 4. LRP6 is a direct target of miR-202. (A) Schematic representation of the mature miR-202 sequence, a miR-202 mutant containing three altered nucleotides in the seed
sequence (miR-202-mut), and miR-202 target sites in the 30-UTR of LRP6 mRNA. (B) Western blotting analysis of the expression levels of LRP6 protein in HCC cells
overexpressing miR-202 or transfected with miR-202 inhibitor, compared with NC; a-Tubulin served as a loading control. (C) Luciferase assay of pGL3-LRP6-30UTR reporter
cotransfected the miR-202 mimic or miR-202-mut (10, 50 nM) in indicated cells, or miR-202 inhibitor (50, 100 nM). (D) Real-time PCR analysis of mRNA expression of genes,
Cyclin D1, MYC and LEF1, in indicated HCC cells. (E) Expression of c-Myc, Cyclin D1, phosphorylated Rb, and Rb protein, as measured by western blotting, in indicated HCC
cells; a-Tubulin served as a loading control. (F) The expression of miR-202 and LRP6 protein in eight HCC tissues (Presented as T1–T8, previously used in Fig. 1B), measured by
real-time PCR analysis and western blotting, respectively; The correlation between miR-202 and LRP6 expression level was analyzed by SPSS software (lower panel). Each bar
represents the mean ± S.D. of three independent experiments. ⁄P < 0.05.
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ulated by miR-202, and upregulated by the miR-202 inhibitor
(Fig. 4D). Furthermore, the expression of c-Myc, Cyclin D1,
b-catenin and phosphorylated Rb protein were downregulated in
miR-202 overexpressing cells, and upregulated in cells transfected
with the miR-202 inhibitor (Fig. 4E). In addition, we also examined
the expression of miR-202 and LRP6 in eight HCC tissues and
analyzed the correlation between them. The results showed an
obviously negative correlation between the expression ofmiR-202 and the LRP6 protein levels (Fig. 4F). Taken together,
our results suggested that LRP6 mRNA is a direct target of miR-
202 in HCC cells.
3.5. LRP6 suppression is essential for miR-202-inhibited cell
proliferation in HCC
To examine the effect of LRP6 suppression on miR-202-
inhibited cell proliferation in HCC, we suppressed endogenous
Y. Zhang et al. / FEBS Letters 588 (2014) 1913–1920 1919LRP6 expression with a LRP6-speciﬁc siRNA (Fig. 5A). Silencing
LRP6 in miR-202 inhibitor or NC transfected cells decreased the
growth rate and proliferation of cells, as assessed by MTT and col-
ony formation assays (Fig. 5B and C). The anchorage-independent
growth ability of miR-202-inhibited cells was also signiﬁcantly
suppressed in response to LRP6 inhibition (Fig. 5D). These results
revealed that further silencing of LRP6 expression in miR-202-
inhibited cells reversed the promoting effect of the miR-202 inhib-
itor on the proliferative capacity of HCC cells. It further conﬁrmed
that depletion of LRP6 is essential for miR-202-mediated inhibition
of proliferation of HCC cells.
4. Discussion
Dysregulation of miRNAs frequently occurs in various human
cancers, and aberrant expression of miRNAs might contribute to
human carcinogenesis by affecting the expression of multiple tar-
get genes [6,8,23]. Therefore, a comprehensive understanding of
the relationship between speciﬁc miRNAs and tumor development
is valuable for the diagnosis and therapy of tumors.Fig. 5. miR-202 promotes proliferation of HCC cells via LRP6 inhibition. (A) Western blot
HCC cells that were transfected with a LRP6-siRNA; a-Tubulin served as a loading control.
colonies formed by the indicated HCC cell lines 10 days after inoculation. (D) Quantiﬁcat
growth assay; colonies larger than 0.1 mm in diameter were scored. Error bars represenmiR-202 has been reported to function as a novel tumor
suppressor in gastric cancer, and its anti-tumor activity may be
attributed the direct targeting and inhibition of glioma-associated
oncogene homolog 1 (Gli1) [12]. Another study showed that
miR-202 directly targets proto-oncogene MYCN, resulting in the
inhibition of neuroblastoma cell proliferation [24]. These previous
studies indicated a possible role of miR-202 during tumor develop-
ment. However, the function of miR-202 in HCC development had
not been elucidated. Our study revealed that miR-202 is downreg-
ulated in HCC cell lines and tissues, indicating a potential function
of miR-202 in HCC progression. Ectopic expression of miR-202 sup-
pressed the proliferation and tumorigenicity of HCC cells in vitro,
while inhibition of miR-202 led to the promotion of cell prolifera-
tion. The mechanism of the tumor-suppressive function of miR-
202 might operate via downregulation of LPR6 by targeting its
30-UTR. We demonstrated that miR-202 might have important role
during HCC progression through a LRP6-mediated signal pathway.
LRP6 has been reported to function as an onco-protein and to
promote the progression of various tumor s through regulation of
the Wnt/b-catenin signaling pathway. The Wnt/b-catenin signalingting analysis of the expression levels of LRP6 in miR-202 inhibitor or NC transfected
(B) MTT-analysis of the growth rates in LRP6-silenced cells. (C) Quantiﬁcation of cell
ion of colony numbers of indicated cells determined by an anchorage-independent
t the mean ± S.D. from three independent experiments. ⁄P < 0.05.
1920 Y. Zhang et al. / FEBS Letters 588 (2014) 1913–1920pathway is activated in various tumors and might play essential
roles during tumor progression [25,26]. LRP6 has been reported
to function as an indispensable co-receptor for the Wnt signaling
pathway by interacting with several components of the pathway
[18,27,28]. Overexpression of LRP6 contributes to the hyperactiva-
tion of the Wnt/b-catenin signaling pathway in human HCCs and
may play a role in hepato-carcinogenesis [20]. Another report sug-
gested that LRP6 expression increases cytosolic b-catenin levels
and TCF/LEF transcriptional activity, and enhances Wnt/b-catenin
signaling activity, to promote cancer cell proliferation both
in vitro and in vivo [18]. In our study, we found that inhibition of
LRP6 by miR-202 resulted in downregulation of the Cyclin D1,
MYC and LEF1 genes, which are the downstream target genes of
the Wnt/b-catenin signaling pathway. These results indicated that
the tumor suppressive function of miR-202 might be correlated
with modulation of the Wnt/b-catenin signaling pathway. Consid-
ering the importance of the Wnt/b-catenin signaling pathway in
tumorigenesis, including HCC, and the regulatory role of LRP6 in
this signaling pathway, further study is needed to clarify the corre-
lation between miR-202 and Wnt/b-catenin signaling.
In conclusion, the current study revealed that miR-202 is down-
regulated in HCC cells and tissues, and that ectopic expression of
miR-202 inhibits, while anti-miR-202 enhances, the proliferation,
tumorigenicity and cell cycle progression of HCC cells. Further-
more, we found that the putative oncogene LRP6 is a direct target
of miR-202, and miR-202 suppresses LRP6 expression transcrip-
tionally by binding to the 30-UTR of its mRNA. Finally, we revealed
that inhibition of LRP6 expression is essential for the tumor sup-
pressive function of miR-202 during HCC progression. All the re-
sults indicated that miR-202 plays an important role during HCC
carcinogenesis and may serve as a putative target for HCC diagno-
sis and therapy.
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